6/2/2023 8:30:40 AM
Novartis : Kisqali Reduces Risk Of Recurrence By 25% Across Broad Population Of Patients With Early Breast Cancer
6/1/2023 1:41:21 AM
Sandoz To Remain Based In Basel, Switzerland Following Proposed Spin-off From Novartis
5/25/2023 1:17:43 AM
Sandoz: EMA Accepts Marketing Authorization Applications For Denosumab For Regulatory Review
5/22/2023 7:56:34 AM
AVROBIO Agrees To Sell Cystinosis Gene Therapy Program To Novartis For $87.5 Mln Cash
5/4/2023 1:46:03 AM
Sandoz Inks Distribution Deal With Adalvo For Exclusive Sandoz Rights To Commercialize Six Products In US
4/26/2023 10:29:08 AM
Novartis To Present New Data Across Oncology Portfolio Including Kisqali Phase III Trial In Early Breast Cancer At ASCO
4/26/2023 6:27:03 AM
Novartis Says Phase III APPOINT-PNH Trial Meets Primary Endpoint
4/25/2023 1:02:05 AM
Novartis Q1 EPS $1.09; Core EPS $1.71
4/20/2023 1:28:36 AM
Novartis Announces New Long-term Data From ALITHIOS Open-label Extension Study